Saposin C
- Generic Name
- Saposin C
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 2N62LTC861
- Background
Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
- Conditions
- Metastatic Colorectal CarcinomaNeuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT05322590
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UC Irvine Health, Orange, California, United States
🇺🇸Pacific Hematology Oncology Associates, San Francisco, California, United States
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
- Conditions
- Neuropathy;PeripheralChemotherapy-induced Peripheral Neuropathy
- Interventions
- Other: Placebo
- First Posted Date
- 2022-03-22
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05291286
- Locations
- 🇺🇸
The Ohio State Unviersity, Columbus, Ohio, United States
🇺🇸CTI Clinical Research Center, Cincinnati, Ohio, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
- Conditions
- Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04771897
- Locations
- 🇺🇸
Nationwide Children's, Columbus, Ohio, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Continued Treatment for Participants Enrolled in Studies of BXQ-350
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04404569
- Locations
- 🇺🇸
University of Cincinnati Barrett Center, Cincinnati, Ohio, United States
🇺🇸University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03967093
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Nationwide Children's, Columbus, Ohio, United States
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Bexion Pharmaceuticals, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT02859857
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.